Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC filing details

Document Details

Form
SC 13G
Filing Date
Apr 10, 2017
Document Date
Apr 10, 2017
Form Description
A statement of beneficial ownership of common stock by certain persons
Filing Group
Other
Company
Blueprint Medicines Corp.
Issuer
Blueprint Medicines Corp